According to the New York State Department of Health, carcinoid tumors are rare. It accounts for 1% of all cancers. The average age of onset for carcinoid tumors is in the early 60s. According to the American Cancer Society, in the United States, approximately 8,000 carcinoid tumors and cancers which start in the gastrointestinal tract are diagnosed each year. The treatment for carcinoid tumor includes surgery, medications, chemotherapy, and targeted drug therapy among others. Several drugs are under clinical trials to evaluate the safety of drugs including immunotherapies. These emerging drugs are expected to slow down the progression of tumor.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing carcinoid tumor pipeline development activities related to carcinoid tumor is covered. Moreover, carcinoid tumor collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
The treatment of carcinoid tumor depends on the size and location of tumor, the types of hormones the tumor secretes, including, medications to control excess hormones, chemotherapy, targeted drug therapy, drugs which deliver radiation directly to the cancer cells, and surgery among others. Medications which are used to control excel hormones are given to slow down tumor growth. Octreotide and lanreotide are administered as injections under the skin. Telotristat is a pill which is used in combination with octreotide or lanreotide sometimes to reduce the symptoms of carcinoid syndrome.
When surgery doesn’t work, chemotherapy is recommended for treating advanced carcinoid tumors. Several studies and research continue to find ways to prevent and manage symptoms of carcinoid tumors. Recent studies have examined the safety of the drug called everolimus against advanced carcinoid tumors. It revealed promising results and proved effective when used to target tumors. This drug was approved by the US FDA in 2016 as a treatment for carcinoid tumors. The changing dynamics are impacting the carcinoid tumor clinical trial landscape significantly.
The objective of the study is to evaluate the SOM230 in patients suffering with metastatic carcinoid tumors. The trial is sponsored by Novartis Pharmaceuticals and is currently under phase II.
This product will be delivered within 3-5 business days.
Report Coverage
The Carcinoid Tumor Pipeline Insight Report by the publisher gives comprehensive insights into carcinoid tumors clinical trials. It covers various aspects related to the details of each of these drugs under development for carcinoid tumor. The report includes the analysis of over 20+ pipeline drugs and 10+ companies. The carcinoid tumor pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from carcinoid tumor.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing carcinoid tumor pipeline development activities related to carcinoid tumor is covered. Moreover, carcinoid tumor collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Carcinoid Tumor Drug Pipeline Outlook
Carcinoid tumors are slow-growing cancer which can arise in different places throughout the body. Carcinoid tumors are one subset of neuroendocrine tumors that begin usually in the digestive tract or in the lungs. These tumors often don't cause signs and symptoms until reach a later stage. Carcinoid tumors release hormones into the body which cause signs and symptoms including diarrhea or skin flushing. Statistics say that less than 10% of people with carcinoid tumors show symptoms. However, the incidence of symptoms varies based on the location and size of the tumor. Since carcinoid tumors grow slowly, they are not diagnosed usually until age 55-65.The treatment of carcinoid tumor depends on the size and location of tumor, the types of hormones the tumor secretes, including, medications to control excess hormones, chemotherapy, targeted drug therapy, drugs which deliver radiation directly to the cancer cells, and surgery among others. Medications which are used to control excel hormones are given to slow down tumor growth. Octreotide and lanreotide are administered as injections under the skin. Telotristat is a pill which is used in combination with octreotide or lanreotide sometimes to reduce the symptoms of carcinoid syndrome.
When surgery doesn’t work, chemotherapy is recommended for treating advanced carcinoid tumors. Several studies and research continue to find ways to prevent and manage symptoms of carcinoid tumors. Recent studies have examined the safety of the drug called everolimus against advanced carcinoid tumors. It revealed promising results and proved effective when used to target tumors. This drug was approved by the US FDA in 2016 as a treatment for carcinoid tumors. The changing dynamics are impacting the carcinoid tumor clinical trial landscape significantly.
Carcinoid Tumor - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of carcinoid tumor drug candidates based on several segmentations including:By Phase
The pipeline assessment report covers 50+ drug analyses based on phase.- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The carcinoid tumor assessment report covers 50+ drug analyses based on drug classes:
- Monoclonal Antibody
- Peptides
- Polymer
- Small Molecule
- Gene Therapy
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.- Oral
- Parenteral
- Others
Carcinoid Tumor - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for carcinoid tumors.Carcinoid Tumor - Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under carcinoid tumor pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapy. Numerous studies are evaluating the safety of monoclonal antibodies to manage the condition. Monoclonal antibodies such as bevacizumab block tumor growth in several ways as some block tumor cells from growing and spreading while others kill them or carry tumor-killing substances to them. They also stop the growth of cancer by blocking the flow of blood to tumor. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for carcinoid tumor.Carcinoid Tumor Clinical Trials Therapeutic Assessment - Competitive Dynamics
The carcinoid tumor report insights covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in carcinoid tumor clinical trials:- Novartis Pharmaceuticals
- CASI Pharmaceuticals, Inc.
- Crinetics Pharmaceuticals Inc.
- Molecular Insight Pharmaceuticals, Inc.
- Neotropix
- Ipsen
- Cylene Pharmaceuticals
- Lexicon Pharmaceuticals
- TerSera Therapeutics LLC
- Endo Pharmaceuticals
- Trio Medicines Ltd.
- Others
Carcinoid Tumor - Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for carcinoid tumor. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of carcinoid tumor drug candidates.Drug: 40 mg Paltusotine
The trial is designed to evaluate the safety, and pharmacokinetics (PK) of paltusotine treatment in patients with carcinoid syndrome. The trial is sponsored by Crinetics Pharmaceuticals and is currently under phase II.Drug: Pasireotide (SOM230
)The objective of the study is to evaluate the SOM230 in patients suffering with metastatic carcinoid tumors. The trial is sponsored by Novartis Pharmaceuticals and is currently under phase II.
Drug: Quarfloxin
Cylene Pharmaceuticals is developing the drug and is currently under phase II. The study is being conducted to evaluate the safety of quarfloxin in patients. The study is evaluating the rate of clinical benefit response to quarfloxin treatment.Reasons To Buy This Report
The Carcinoid Tumor Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for carcinoid tumor. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into carcinoid tumor collaborations, regulatory environments, and potential growth opportunities within carcinoid tumor pipeline insights.Key Questions Answered in the Carcinoid Tumor - Pipeline Insight Report
- What is the current landscape of carcinoid tumor pipeline drugs?
- How many companies are developing carcinoid tumors?
- How many phase III and phase IV drugs are currently present in carcinoid tumor pipeline drugs?
- Which companies/institutions are leading the carcinoid tumor development?
- What is the efficacy and safety profile of carcinoid tumor pipeline drugs?
- What are the opportunities and challenges present in the carcinoid tumor pipeline landscape?
- Which company is conducting major trials for carcinoid tumors?
- What geographies are covered carcinoid tumor for clinical trials?
- What are emerging trends in carcinoid tumor clinical trials?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Carcinoid Tumor
4 Patient Profile: Carcinoid Tumor
5 Carcinoid Tumor: Epidemiology Snapshot
6 Carcinoid Tumor: Market Dynamics
7 Carcinoid Tumor: Key Facts Covered
8 Carcinoid Tumor, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Carcinoid Tumor Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Carcinoid Tumor Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Carcinoid Tumor Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Carcinoid Tumor Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Carcinoid Tumor, Key Drug Pipeline Companies
